Processing

Please wait...

Settings

Settings

Goto Application

1. WO2003046141 - METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS

Publication Number WO/2003/046141
Publication Date 05.06.2003
International Application No. PCT/US2002/037899
International Filing Date 26.11.2002
Chapter 2 Demand Filed 20.06.2003
IPC
C12N 15/87 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
CPC
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A61P 5/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
C12N 15/873
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
873Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
Applicants
  • ADVANCED CELL TECHNOLOGY, INC. [US]/[US] (AllExceptUS)
  • CIBELLI, Jose [US]/[US] (UsOnly)
  • WEST, Michael [US]/[US] (UsOnly)
  • CAMPBELL, Keith [GB]/[GB] (UsOnly)
Inventors
  • CIBELLI, Jose
  • WEST, Michael
  • CAMPBELL, Keith
Agents
  • CROWELL & MORING, L.L.P
Priority Data
60/332,51026.11.2001US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS
(FR) PROCEDES DE PRODUCTION ET D'UTILISATION DE NOYAUX DE CELLULES SOMATIQUES HUMAINES REPROGRAMMEES ET DE CELLULES SOUCHES HUMAINES AUTOLOGUES ET ISOGENIQUES
Abstract
(EN) Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. In one embodiment, the invention provides methods for producing activated human embryos by parthenogenesis; in another embodiment, the invention provides methods for producing activated human embryos by somatic cell nuclear transfer whereby the genetic material of a differentiated human donor cell is reprogrammed to form a diploid human pronucleus capable of directing a cell to generate the stem cells from which autologous, isogenic cells for transplantation therapy are derived. The ability to create autologous human embryos represents a critical step towards generating immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development.
(FR) Selon l'invention, des embryons humains activés produits par clonage thérapeutique peuvent engendrer des cellules souches humaines totipotentes et pluripotentes dont sont issues les cellules autologues destinées au traitement par transplantation. L'invention concerne également des procédés permettant de produire des embryons humains activés pouvant être utilisés pour engendrer des cellules souches totipotentes et pluripotentes dont sont issus les cellules et les tissus autologues aptes à la transplantation. Dans un mode de réalisation, l'invention concerne des procédés permettant de produire des embryons humains activés, par parthénogenèse. Dans un autre mode de réalisation, l'invention concerne des procédés permettant de produire des embryons humains activés, par transfert de noyaux de cellules somatiques, le matériel génétique d'une cellule donatrice humaine différenciée étant reprogrammé pour former un pronucleus humain diploïde pouvant diriger une cellule pour engendrer les cellules souches dont sont issues les cellules autologues et isogéniques destinées au traitement par transplantation. La possibilité de créer des embryons humains autologues constitue une avancée importante dans la production de cellules souches à compatibilité immunitaire pouvant être utilisées pour résoudre le problème du rejet immunitaire en médecine régénératrice. Les embryons humains activés produits selon la présente invention fournissent également des systèmes modèles permettant d'identifier et d'analyser les mécanismes moléculaires de l'empreinte épigénétique et de la régulation génétique de l'embryogenèse et du développement.
Latest bibliographic data on file with the International Bureau